Eli Lilly and Co. reported that its phase 4 study, IXORA-R, met the primary endpoint of patients treated with Taltz showing statistically significant improvement in the Psoriasis Area Severity Index 100 score compared with patients on Tremfya at week 12.
In the study, 1,027 patients with moderate to severe plaque psoriasis were enrolled and randomly assigned to Taltz (ixekizumab, Eli Lilly) or Tremfya (guselkumab, Janssen) for a total of 24 weeks.
Patients in the Tremfya group received 100 mg at weeks 0, 4, 12 and 20. Patients assigned Taltz received 160 mg at week 0, and then 80 mg at weeks 2, 4, 6, 8, 10, 12, 16 and 20, study investigator Andrew Blauvelt, MD, MBA, dermatologist and president of Oregon Medical Research Center in Portland, told Healio Dermatology.
Patients achieving Psoriasis Area Severity Index (PASI) 100 at week 12 accounted for 41.3% in the ixekizumab group vs. 24.9% in the guselkumab group (P < .001), according to a Lilly press release.
“Health care providers and patients value speed of response when evaluating treatment options for moderate to severe plaque psoriasis,” Blauvelt said in the release. “The results from the IXORA-R study demonstrate that Taltz was effective in helping more patients achieve completely clear skin by week 12 with a 50% improvement in skin plaques seen as early as week 1.”
Secondary endpoints of the study include proportion of patients achieving PASI 75 at week 2, PASI 90 at weeks 4 and 8, PASI 100 at weeks 4, 8 and 24, static Physician’s Global Assessment (sPGA) at week 12 and PASI 50 at week 1. All major secondary endpoints up to week 12 were achieved (P < .001), according to Lilly.
IXORA-R is ongoing and Lilly plans to share the results on additional key secondary endpoints of patients achieving PASI 100 at 24 weeks in 2020.
Disclosure: Blauvelt is lead study investigator for IXORA-R and president of Oregon Medical Research Center.